# Evaluation of the use of different forms of medical cannabis in the treatment of fibromyalgia: a systematic review

> **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637)
> **Publisher:** CED Clinic (https://cedclinic.com)
> **Canonical URL:** https://cedclinic.com/research/medical-cannabis-for-fibromyalgia-systematic-review/
> **Published:** 2026-10-14T18:51:44-04:00 | **Last Modified / Clinically Audited:** 2026-10-20T13:33:25-04:00
> **Clinical Summary:** Researchers reviewed the best available medical studies that tested cannabis-based medicines in people with a long-lasting condition that causes.

---

Objectives: To systematically review, based on randomised controlled trials (RCTs), some forms of medical cannabis (nabilone, tetrahydrocannabinol-rich oil, and Bediol) in the treatment of fibromyalgia syndrome (FMS). Methods: PRISMA-guided systematic review; databases Medline/PubMed, Embase, CENTRAL and Scopus; inclusion of RCTs in adults with fibromyalgia by ACR criteria comparing medical cannabis with placebo or current therapy. Results: Only 4 articles were eligible. From them, it was not possible to infer the real impact after the use of 3 forms of medical cannabis (alone or associated with another therapy) on disease, pain, or insomnia. Conclusions: It is not possible to conclude whether different forms of medical cannabis are an effective and safe therapeutic option for the treatment of FMS symptoms, with tolerable adverse effects. This prescription should be made individually for each patient.

 

### Related

---

### Verification & Medical Governance

- **Lead Clinical Author:** Benjamin Caplan, MD
- **Credentials:** Board Certified in Family Medicine (ABFM), Former CMO Canna Care Docs (250,000+ patients supervised), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House).
- **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`).
- **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/).
- **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637).
- **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).